Irish biotechnology firm Alkermes has received fast-track designation for its proprietary investigational medicine ALKS 5461 from the US Food and Drug Administration (FDA).

Fast-track designation was granted for the adjunctive treatment of patients with major depressive disorder (MDD) who don’t respond to standard therapies. The process intended to speed-up the review of drugs, which treat serious conditions and fill an unmet medical need.

The drug, ALKS 5461, “significantly reduced” symptoms of depression in the 142-patient study, from the second of three phases of clinical trials generally required for regulatory approval, Alkermes said today in a statement. Based on the results, the company plans to request a meeting with the U.S. Food and Drug Administration and start later-stage studies.“We had been deliberately modest with folks over the last year because it’s so potentially important we thought we should be skeptical until we see a confirmatory study,” Alkermes Chief Executive Officer Richard Pops said in a telephone interview today. “The result was so clear when we un-blinded that it was self-evident that we needed to keep going.”

Patients Tested
Alkermes’s drug was tested in patients for whom other medicines, called selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, haven’t worked as well as hoped. Treatments in those classes include Eli Lilly & Co. (LLY)’s Prozac and Cymbalta. ALKS 5461 was tested on top of drugs patients were already taking as that may be the way the medicine would be used if approved, Pops said.

“This is a potentially very important positive development for Alkermes as ALKS 5461 is an oral, once-a-day drug which has a novel mechanism of action for treating MDD, which represents a very large market opportunity,” Cory Kasimov, an analyst with JPMorgan Chase & Co. (JPM), wrote in a research note today.

About 16.1 million people in the U.S. experience major depressive disorder, or MDD, each year and many don’t get enough of a benefit from the first antidepressants they try, according to Alkermes. Of about 10 million patients who receive treatment for MDD, two-thirds aren’t adequately helped and try a second therapy, Pops said.

ALKS 5461 is a combination of another compound, ALKS 33, and buprenorphine, a therapy that stimulates the opioid system and is approved for treatment of addiction to opioids such as heroin.

The company decided to test the combination based on the premise that opioids have been shown to help in treatment of depression. The problem was their addictive properties, Pops said. ALKS 33 is an opioid receptor blocker, and its use is designed to combat addictive effects.

“We wanted to know if you can decouple the addictive properties of an opioid from antidepressive properties,” Pops said. With ALKS 5461, “we’re pushing the gas and the brake at the same time.”

Alkermes is equipped to start a bigger trial on its own, and may talk with pharmaceutical companies about partnerships to sell the drug outside the U.S. if it’s approved, Pops said, noting “it’s too early” to discuss commercial plans

EMAIL SUBSCRIPTION FOR THIS BLOG

SUBSCRIBE BY EMAIL TO ALL ABOUT DRUGS

Feedburner form

DISCLAIMER

“ALL FOR DRUGS” CATERS TO EDUCATION GLOBALLY, No commercial exploits are done or advertisements added by me. This is a compilation for educational purposes only.
P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 29 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international,
etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules
and implementation them on commercial scale over a 29 year tenure till date Aug 2016, Around 30 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 25 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 13 lakh plus views on New Drug Approvals Blog in 212 countries......http://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

The first continuous flow synthesis of C8–C16 alkane fuel precursors from biobased platform molecules is reported. TBD (1,5,7-triazabicyclo[4.4.0]dec-5-ene) was found to be a recyclable and highly efficient organic base catalyst for the aldol condensation of furfural with carbonyl compounds, and the selectivity of mono- or difuryl product can be easily regulated by adjusting […]

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP
ALL ABOUT DRUGS